Mirvetuximab Soravtansine
OncoPharm
00:00
Pharmacokinetics and Drug‑Drug Interaction Risks
John asks about metabolism and covers DM4/ metabolite half‑lives, CYP3A/4 metabolism, and potential interaction concerns without formal studies.
Play episode from 11:03
Transcript
